FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use
Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:FGFR2-C10orf118

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: FGFR2-C10orf118
FusionPDB ID: 30278
FusionGDB2.0 ID: 30281
HgeneTgene
Gene symbol

FGFR2

C10orf118

Gene ID

2263

55088

Gene namefibroblast growth factor receptor 2coiled-coil domain containing 186
SynonymsBBDS|BEK|BFR-1|CD332|CEK3|CFD1|ECT1|JWS|K-SAM|KGFR|TK14|TK25C10orf118|CCCP-1|golgin104
Cytomap

10q26.13

10q25.3

Type of geneprotein-codingprotein-coding
Descriptionfibroblast growth factor receptor 2BEK fibroblast growth factor receptorbacteria-expressed kinasekeratinocyte growth factor receptorprotein tyrosine kinase, receptor like 14coiled-coil domain-containing protein 186CTCL tumor antigen HD-CL-01/L14-2CTCL tumor antigen L14-2
Modification date2020032220200313
UniProtAcc

P21802

Main function of 5'-partner protein: FUNCTION: Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1. {ECO:0000269|PubMed:12529371, ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:15629145, ECO:0000269|PubMed:16384934, ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18374639, ECO:0000269|PubMed:19103595, ECO:0000269|PubMed:19387476, ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21596750, ECO:0000269|PubMed:8663044}.		.
Ensembl transtripts involved in fusion geneENST idsENST00000346997, ENST00000351936, 
ENST00000356226, ENST00000357555, 
ENST00000358487, ENST00000360144, 
ENST00000369056, ENST00000369059, 
ENST00000369060, ENST00000369061, 
ENST00000457416, ENST00000478859, 
ENST00000359354, ENST00000490349, 
ENST00000369285, ENST00000369286, 
ENST00000497592, ENST00000543782, 
ENST00000369287, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score24 X 20 X 12=57601 X 1 X 1=1
# samples 381
** MAII scorelog2(38/5760*10)=-3.92199748799873
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(1/1*10)=3.32192809488736
Fusion gene context

PubMed: FGFR2 [Title/Abstract] AND C10orf118 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: FGFR2 [Title/Abstract] AND C10orf118 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)FGFR2(123243212)-C10orf118(115910979), # samples:2
Anticipated loss of major functional domain due to fusion event.FGFR2-C10orf118 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
FGFR2-C10orf118 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
FGFR2-C10orf118 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
FGFR2-C10orf118 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
FGFR2-C10orf118 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF.
FGFR2-C10orf118 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
FGFR2-C10orf118 seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneFGFR2

GO:0008284

positive regulation of cell proliferation

8663044

HgeneFGFR2

GO:0008543

fibroblast growth factor receptor signaling pathway

8663044|15629145

HgeneFGFR2

GO:0018108

peptidyl-tyrosine phosphorylation

15629145|16844695

HgeneFGFR2

GO:0046777

protein autophosphorylation

15629145



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:123243212/chr10:115910979)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across FGFR2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across C10orf118 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000369061FGFR2chr10123243212-ENST00000369287C10orf118chr10115910979-833421154840521334
ENST00000346997FGFR2chr10123243212-ENST00000369287C10orf118chr10115910979-852623071242441410
ENST00000369056FGFR2chr10123243212-ENST00000369287C10orf118chr10115910979-854723282442651413

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000369061ENST00000369287FGFR2chr10123243212-C10orf118chr10115910979-0.0001008850.99989915
ENST00000346997ENST00000369287FGFR2chr10123243212-C10orf118chr10115910979-7.68E-050.9999232
ENST00000369056ENST00000369287FGFR2chr10123243212-C10orf118chr10115910979-8.84E-050.99991167

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for FGFR2-C10orf118

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
FGFR2chr10123243212C10orf118chr101159109792115689EDLDRILTLTTNELESRIEELNKEVK
FGFR2chr10123243212C10orf118chr101159109792307765EDLDRILTLTTNELESRIEELNKEVK
FGFR2chr10123243212C10orf118chr101159109792328768EDLDRILTLTTNELESRIEELNKEVK

Top

Potential FusionNeoAntigen Information of FGFR2-C10orf118 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
FGFR2-C10orf118_123243212_115910979.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
FGFR2-C10orf118chr10123243212chr101159109792307HLA-B08:01ELESRIEEL0.97840.77471221
FGFR2-C10orf118chr10123243212chr101159109792307HLA-A02:22ILTLTTNEL0.97270.5486514
FGFR2-C10orf118chr10123243212chr101159109792307HLA-A02:13ILTLTTNEL0.92930.6468514
FGFR2-C10orf118chr10123243212chr101159109792307HLA-A02:27ILTLTTNEL0.92010.5609514
FGFR2-C10orf118chr10123243212chr101159109792307HLA-A02:04ILTLTTNEL0.8780.578514
FGFR2-C10orf118chr10123243212chr101159109792307HLA-A02:38ILTLTTNEL0.86580.6081514
FGFR2-C10orf118chr10123243212chr101159109792307HLA-A02:19ELESRIEEL0.22620.52851221
FGFR2-C10orf118chr10123243212chr101159109792307HLA-B39:13NELESRIEEL0.94920.92621121
FGFR2-C10orf118chr10123243212chr101159109792307HLA-C01:17ILTLTTNEL0.48250.9359514
FGFR2-C10orf118chr10123243212chr101159109792307HLA-C01:30ILTLTTNEL0.07850.96514
FGFR2-C10orf118chr10123243212chr101159109792307HLA-B08:18ELESRIEEL0.97840.77471221
FGFR2-C10orf118chr10123243212chr101159109792307HLA-B08:12ELESRIEEL0.93610.88041221
FGFR2-C10orf118chr10123243212chr101159109792307HLA-A69:01TTNELESRI0.90930.7414918
FGFR2-C10orf118chr10123243212chr101159109792307HLA-C01:03ILTLTTNEL0.70820.9377514
FGFR2-C10orf118chr10123243212chr101159109792307HLA-B15:73ILTLTTNEL0.58890.9394514
FGFR2-C10orf118chr10123243212chr101159109792307HLA-B15:30ILTLTTNEL0.53630.9033514
FGFR2-C10orf118chr10123243212chr101159109792307HLA-C01:02ILTLTTNEL0.49180.9322514
FGFR2-C10orf118chr10123243212chr101159109792307HLA-B40:04NELESRIEEL0.99840.67541121
FGFR2-C10orf118chr10123243212chr101159109792307HLA-B41:03NELESRIEEL0.98430.59911121

Top

Potential FusionNeoAntigen Information of FGFR2-C10orf118 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
FGFR2-C10orf118_123243212_115910979.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0102LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0123LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0403LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0411LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0411DRILTLTTNELESRI318
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0417LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0424LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0427LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0439LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0441LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0442LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0444LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0446LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0449LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0450LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0450DRILTLTTNELESRI318
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0451LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0452LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0456LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0459LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0460LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0467LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0467DRILTLTTNELESRI318
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0469LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0471LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0478LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0478DRILTLTTNELESRI318
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0479LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0482LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0485LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0488LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0488DRILTLTTNELESRI318
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0491LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-0491DRILTLTTNELESRI318
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1201LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1203LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1205LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1206LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1207LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1208LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1210LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1211LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1212LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1213LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1214LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1215LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1217LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1218LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1219LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1221LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1222LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1223LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1410LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1410DRILTLTTNELESRI318
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1410DLDRILTLTTNELES116
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1534LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1615LDRILTLTTNELESR217
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1615DRILTLTTNELESRI318
FGFR2-C10orf118chr10123243212chr101159109792307DRB1-1615DLDRILTLTTNELES116

Top

Fusion breakpoint peptide structures of FGFR2-C10orf118

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
5717LTLTTNELESRIEEFGFR2C10orf118chr10123243212chr101159109792307

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of FGFR2-C10orf118

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN5717LTLTTNELESRIEE-7.15543-7.26883
HLA-B14:023BVN5717LTLTTNELESRIEE-4.77435-5.80965
HLA-B52:013W395717LTLTTNELESRIEE-6.80875-6.92215
HLA-B52:013W395717LTLTTNELESRIEE-4.20386-5.23916
HLA-A11:014UQ25717LTLTTNELESRIEE-7.5194-8.5547
HLA-A11:014UQ25717LTLTTNELESRIEE-6.9601-7.0735
HLA-A24:025HGA5717LTLTTNELESRIEE-7.52403-7.63743
HLA-A24:025HGA5717LTLTTNELESRIEE-5.82433-6.85963
HLA-B27:056PYJ5717LTLTTNELESRIEE-3.28285-4.31815
HLA-B44:053DX85717LTLTTNELESRIEE-5.91172-6.94702
HLA-B44:053DX85717LTLTTNELESRIEE-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of FGFR2-C10orf118

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
FGFR2-C10orf118chr10123243212chr101159109791121NELESRIEELAATGAGTTAGAATCAAGAATAGAAGAACTT
FGFR2-C10orf118chr10123243212chr101159109791221ELESRIEELGAGTTAGAATCAAGAATAGAAGAACTT
FGFR2-C10orf118chr10123243212chr10115910979514ILTLTTNELATTCTCACTCTCACAACCAATGAGTTA
FGFR2-C10orf118chr10123243212chr10115910979918TTNELESRIACAACCAATGAGTTAGAATCAAGAATA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
FGFR2-C10orf118chr10123243212chr10115910979116DLDRILTLTTNELESGACTTGGATCGAATTCTCACTCTCACAACCAATGAGTTAGAATCA
FGFR2-C10orf118chr10123243212chr10115910979217LDRILTLTTNELESRTTGGATCGAATTCTCACTCTCACAACCAATGAGTTAGAATCAAGA
FGFR2-C10orf118chr10123243212chr10115910979318DRILTLTTNELESRIGATCGAATTCTCACTCTCACAACCAATGAGTTAGAATCAAGAATA

Top

Information of the samples that have these potential fusion neoantigens of FGFR2-C10orf118

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
CHOLFGFR2-C10orf118chr10123243212ENST00000346997chr10115910979ENST00000369287TCGA-W5-AA2Z-01A

Top

Potential target of CAR-T therapy development for FGFR2-C10orf118

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneFGFR2chr10:123243212chr10:115910979ENST00000346997-1617378_398765820.0TransmembraneHelical
HgeneFGFR2chr10:123243212chr10:115910979ENST00000351936-1718378_398765786.0TransmembraneHelical
HgeneFGFR2chr10:123243212chr10:115910979ENST00000356226-1516378_398650705.0TransmembraneHelical
HgeneFGFR2chr10:123243212chr10:115910979ENST00000357555-1617378_398678708.0TransmembraneHelical
HgeneFGFR2chr10:123243212chr10:115910979ENST00000358487-1718378_398767822.0TransmembraneHelical
HgeneFGFR2chr10:123243212chr10:115910979ENST00000360144-1617378_398679681.0TransmembraneHelical
HgeneFGFR2chr10:123243212chr10:115910979ENST00000369056-1617378_398768770.0TransmembraneHelical
HgeneFGFR2chr10:123243212chr10:115910979ENST00000369060-1516378_398651706.0TransmembraneHelical
HgeneFGFR2chr10:123243212chr10:115910979ENST00000369061-1415378_398655710.0TransmembraneHelical
HgeneFGFR2chr10:123243212chr10:115910979ENST00000457416-1718378_398768823.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to FGFR2-C10orf118

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to FGFR2-C10orf118

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneFGFR2C2931196Craniofacial dysostosis type 123CTD_human;GENOMICS_ENGLAND;UNIPROT
HgeneFGFR2C0220658Pfeiffer Syndrome21CTD_human;GENOMICS_ENGLAND;UNIPROT
HgeneFGFR2C0001193Apert syndrome19CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgeneFGFR2C0795998JACKSON-WEISS SYNDROME10CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgeneFGFR2C0175699Saethre-Chotzen Syndrome8CTD_human;GENOMICS_ENGLAND;ORPHANET
HgeneFGFR2C1852406Cutis Gyrata Syndrome of Beare And Stevenson8CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgeneFGFR2C2936791Antley-Bixler Syndrome, Autosomal Dominant7CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgeneFGFR2C1510455Acrocephalosyndactylia6CTD_human;ORPHANET
HgeneFGFR2C0265269Lacrimoauriculodentodigital syndrome5CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgeneFGFR2C0010278Craniosynostosis4CTD_human;GENOMICS_ENGLAND
HgeneFGFR2C1863389Apert-Crouzon Disease4CTD_human
HgeneFGFR2C1865070SCAPHOCEPHALY, MAXILLARY RETRUSION, AND MENTAL RETARDATION4CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgeneFGFR2C0006142Malignant neoplasm of breast3CTD_human;UNIPROT
HgeneFGFR2C0030044Acrocephaly3CTD_human
HgeneFGFR2C0036341Schizophrenia3PSYGENET
HgeneFGFR2C0221356Brachycephaly3CTD_human
HgeneFGFR2C0265534Scaphycephaly3CTD_human
HgeneFGFR2C0265535Trigonocephaly3CTD_human
HgeneFGFR2C0376634Craniofacial Abnormalities3CTD_human
HgeneFGFR2C0678222Breast Carcinoma3CTD_human
HgeneFGFR2C1257931Mammary Neoplasms, Human3CTD_human
HgeneFGFR2C1458155Mammary Neoplasms3CTD_human
HgeneFGFR2C1833340Synostotic Posterior Plagiocephaly3CTD_human
HgeneFGFR2C1860819Metopic synostosis3CTD_human
HgeneFGFR2C2931150Synostotic Anterior Plagiocephaly3CTD_human
HgeneFGFR2C3281247BENT BONE DYSPLASIA SYNDROME3CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgeneFGFR2C4551902Craniosynostosis, Type 13CTD_human
HgeneFGFR2C4704874Mammary Carcinoma, Human3CTD_human
HgeneFGFR2C0008925Cleft Palate2CTD_human
HgeneFGFR2C0011570Mental Depression2PSYGENET
HgeneFGFR2C0011581Depressive disorder2PSYGENET
HgeneFGFR2C0024623Malignant neoplasm of stomach2CGI;CTD_human
HgeneFGFR2C0038356Stomach Neoplasms2CGI;CTD_human
HgeneFGFR2C1708349Hereditary Diffuse Gastric Cancer2CTD_human
HgeneFGFR2C1837218Cleft palate, isolated2CTD_human
HgeneFGFR2C0000772Multiple congenital anomalies1CTD_human
HgeneFGFR2C0003090Ankylosis1CTD_human
HgeneFGFR2C0005586Bipolar Disorder1PSYGENET
HgeneFGFR2C0008924Cleft upper lip1CTD_human
HgeneFGFR2C0010273Craniofacial Dysostosis1CTD_human
HgeneFGFR2C0011757Developmental Coordination Disorder1CTD_human
HgeneFGFR2C0014170Endometrial Neoplasms1CTD_human
HgeneFGFR2C0018553Hamartoma Syndrome, Multiple1CTD_human
HgeneFGFR2C0020796Profound Mental Retardation1CTD_human
HgeneFGFR2C0023890Liver Cirrhosis1CTD_human
HgeneFGFR2C0024121Lung Neoplasms1CTD_human
HgeneFGFR2C0025363Mental Retardation, Psychosocial1CTD_human
HgeneFGFR2C0026613Motor Skills Disorders1CTD_human
HgeneFGFR2C0033975Psychotic Disorders1PSYGENET
HgeneFGFR2C0037268Skin Abnormalities1CTD_human
HgeneFGFR2C0037274Dermatologic disorders1CTD_human
HgeneFGFR2C0038219Status Dysraphicus1CTD_human
HgeneFGFR2C0040427Tooth Abnormalities1CTD_human
HgeneFGFR2C0080178Spina Bifida1CTD_human
HgeneFGFR2C0152423Congenital small ears1GENOMICS_ENGLAND
HgeneFGFR2C0206698Cholangiocarcinoma1CTD_human
HgeneFGFR2C0206762Limb Deformities, Congenital1CTD_human
HgeneFGFR2C0239946Fibrosis, Liver1CTD_human
HgeneFGFR2C0242379Malignant neoplasm of lung1CTD_human
HgeneFGFR2C0265326Bannayan-Riley-Ruvalcaba Syndrome1CTD_human
HgeneFGFR2C0266508Rachischisis1CTD_human
HgeneFGFR2C0345905Intrahepatic Cholangiocarcinoma1CTD_human
HgeneFGFR2C0349204Nonorganic psychosis1PSYGENET
HgeneFGFR2C0391826Lhermitte-Duclos disease1CTD_human
HgeneFGFR2C0476089Endometrial Carcinoma1CGI;CTD_human
HgeneFGFR2C0524730Odontome1CTD_human
HgeneFGFR2C0699791Stomach Carcinoma1CGI;GENOMICS_ENGLAND
HgeneFGFR2C0917816Mental deficiency1CTD_human
HgeneFGFR2C1450010Plagiocephaly, Nonsynostotic1CTD_human
HgeneFGFR2C1860042Antley-Bixler Syndrome with Disordered Steroidogenesis1CTD_human
HgeneFGFR2C1867564SCAPHOCEPHALY AND AXENFELD-RIEGER ANOMALY1GENOMICS_ENGLAND
HgeneFGFR2C1959582PTEN Hamartoma Tumor Syndrome1CTD_human
HgeneFGFR2C2350233Antley-Bixler Syndrome Phenotype1CTD_human
HgeneFGFR2C3267076Familial scaphocephaly syndrome1GENOMICS_ENGLAND
HgeneFGFR2C3714756Intellectual Disability1CTD_human
HgeneFGFR2C3805278Extrahepatic Cholangiocarcinoma1CTD_human